miR149 rs71428439 polymorphism and risk of clear cell renal cell carcinoma: a case–control study

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12127-12130

  Wang, Zhigang ^a   Wei, Meng ^a   Ren, Yi ^a   Liu, Hua ^a   Wang, Meng ^a   Shi, Kehui ^a   Jiang, Hongli ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

CCRCC; MicroRNA; miR149; Polymorphism; Renal cell carcinoma

Indexed keywords

GENOMIC DNA; MICRORNA; MICRORNA 149; UNCLASSIFIED DRUG; MIRN149 MICRORNA, HUMAN;

ADULT; ARTICLE; BODY MASS; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; ALLELE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; KIDNEY TUMOR; RISK; RISK FACTOR;

AGED; ALLELES; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS;

EID: 84925285846     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2517-5     Document Type: Article

References (33)

1. Kidney cancer: CXCR4—a prognostic factor for renal cell carcinoma? Nature reviews urology 2014;11:247.
2. Loron MC, Grange S, Guerrot D, Di Fiore F, Freguin C, Hanoy M, Le Roy F, Poussard G, Etienne I, Legallicier B, Pfister C, Godin M, Bertrand D: Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol 2014
3. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal cell carcinoma. Lancet Oncol. 2014;15:e170–7.
4. Lornoy W, Becaus S, de Vleeschouwer M, Morelle V, Fonteyne E, Thienpoint L, et al. Renal cell carcinoma, a new complication of analgesic nephropathy. Lancet. 1986;1:1271–2.
5. Renal cell carcinoma. Lancet 1976;2:887–888.
6. Brugarolas J: Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014
7. Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, et al. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer. 2014;14:25.
8. Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2014;21:83–91.
9. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44:53–8.
10. Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi TP, et al. Down-regulated miR-30a in clear cell renal cell carcinoma correlated with tumor hematogenous metastasis by targeting angiogenesis-specific DLL4. PLoS One. 2013;8:e67294.
11. Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013;108:131–8.
12. Zhao A, Li G, Peoc’h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94:115–20.
13. Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532–46.
14. Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer Educ. 2011;2:515–26.
15. Song T, Zhang X, Wang C, Wu Y, Cai W, Gao J, et al. miR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011;12:1307–11.
16. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29:5724–8.
17. Omrani M, Hashemi M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Arbabi F, et al. hsa-miR-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8:259–67.
18. Chae YS, Kim JG, Lee SJ, Kang BW, Lee YJ, Park JY, et al. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013;33:3233–9.
19. Du W, Ma X, Kong W, Liu T, Wei B, Yu J, et al. Association between rs11614913 polymorphism in miR-196a2 and colorectal cancer risk: a meta-analysis. Cancer Biomark. 2013;13:457–64.
20. Lin Y, Nie Y, Zhao J, Chen X, Ye M, Li Y, et al. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis. 2012;33:2377–83.
21. Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2013;229:12–24.
22. Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Muller D, Olayioye MA: miR-149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res 2014
23. Ke Y, Zhao W, Xiong J, Cao R. miR-149 inhibits non-small-cell lung cancer cells EMT by targeting FOXM1. Biochem res int. 2013;2013:506731.
24. Lin RJ, Lin YC, Yu AL. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010;49:719–27.
25. Ding SL, Wang JX, Jiao JQ, Tu X, Wang Q, Liu F, et al. A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. J Biol Chem. 2013;288:26865–77.
26. Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD, et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 2014;156:893–906.
27. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative mild trial study. J Clin Oncol. 2014;32:768–73.
28. Heneghan HM, Miller N, Kerin MJ: Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010;28:e573-574; author reply e575-576.
29. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138:592–603.
30. Ruvkun G. Clarifications on miRNA and cancer. Science. 2006;311:36–7.
31. Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M. miRNA control of apoptotic programs: focus on ovarian cancer. Expert Rev Mol Diagn. 2011;11:277–86.
32. Wang Y, Zhang X, Li H, Yu J, Ren X. The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013;92:123–8.
33. Zadran S, Remacle F, Levine RD. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci U S A. 2013;110:19160–5.